There was a thread that I started about the newly mandated lengthy Phase3 trial and how it would expand the patient population of NTM...guess who erased a new contributor that we may have lost but understood the dynamic. I will dumbitdown for the poor woman.
"By expanding the trial for the whole disease rather than a subgroup (refractory only), Arikayce would then be a treatment for a much larger patient population. Yes it will take a couple of years and yes it will cost a offering amount, but the FDA wants to approve a expensive drug for many in the disease group. ...Good Luck